[Disclosure] Celltrion (068270) Submits Application for Domestic Marketing Authorization of ‘CT-P55’ (Cosentyx Biosimilar)

Fact Source: Financial Supervisory Service DART / 2026-06-26

Disclosure Type: Major Management Event Related to Investment Judgement

💡 3-Second Summary

Celltrion has officially applied for marketing authorization to the South Korean Ministry of Food and Drug Safety (MFDS) for CT-P55, its biosimilar candidate for the autoimmune disease treatment ‘Cosentyx,’ following successful Phase 1 results demonstrating pharmacokinetic equivalence.

📊 1. [Summary of Key Disclosure Content and Figures]

• Product and Ingredient Name: Cosentyx Biosimilar CT-P55 (Ingredient: Secukinumab)
• Submission Date & Regulatory Authority: June 26, 2026 / Ministry of Food and Drug Safety (MFDS) of South Korea
• Target Indications (Adults): Plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)
• Phase 1 Clinical Trial Data Summary (172 Subjects):
  • Pharmacokinetics (PK): The 90% confidence intervals for primary endpoints AUC0-inf and Cmax fell entirely within the predefined equivalence margins, confirming PK equivalence to the original drug Cosentyx.
  • Safety: Treatment-emergent adverse events occurred in 65.5% of total subjects, showing a similar distribution across groups. Most cases were mild or moderate (only 1 case of a serious adverse event was reported, which occurred in the original Cosentyx group).
  • Immunogenicity: The incidence of ADA (Anti-Drug Antibodies) and NAb (Neutralizing Antibodies) against Secukinumab remained low and comparable among the groups, with no clinically meaningful impact on safety.
• Future Operations: Following this domestic regulatory submission in South Korea, the company intends to consecutively submit regulatory filings in other major countries globally.

📈 2. [Professional Insight: What This Disclosure Means for Investors]

• Transition Into the Commercialization Phase: Shifting from active clinical testing to the regulatory approval review phase marks a distinct operational milestone. Filing the application in South Korea first serves as a tactical pipeline anchor that could accelerate the subsequent regulatory and commercialization timelines globally.
• Validation of Robust Technical Equivalence: The fact that the primary PK metrics (AUC and Cmax) settled well within the tight statistical boundaries of equivalence suggests a high level of bio-similarity. This robust data profile may act as a positive underlying factor during the regulatory agency’s technical evaluation.
• Persistent Regulatory Review Uncertainty: The submission of a marketing application does not guarantee an eventual green light from the MFDS. The review process may involve requests for supplemental documentation or procedural bottlenecks that could delay or alter commercialization goals. Investors should monitor the regulatory approval timeline carefully rather than treating the filing as a definitive final success.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion is adding another layer to its robust autoimmune pipeline with CT-P55, a biosimilar targeting Cosentyx—a multi-billion dollar block-buster IL-17A inhibitor. The filing with the South Korean MFDS is backed by Phase 1 clinical data from 172 subjects, which yielded positive readouts regarding pharmacokinetic parameters, safety metrics, and immunogenicity profiles against the reference product. Although filing an application does not secure an instant product launch, it successfully shifts the candidate from developer risk into institutional review risk. Long-term international investors should focus on how seamlessly Celltrion secures this domestic approval and how quickly it leverages these data points for subsequent FDA or EMA roll-outs.

📢 Disclaimer & Source Information

Source: This content has been structured and newly written based on official disclosure data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Advisory: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice, solicitation, or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the individual investor.

Inquiries: For compliance queries or copyright-related requests, please contact us at ksb220805@gmail.com.